Allogeneic Monocyte Co-differentiation for Non-exhausted Dendritic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing dendritic cells for cancer immunotherapy are inefficient and costly due to the need for custom-made, patient-specific vaccines, which require labor-intensive procedures and result in exhausted cells that are ineffective in inducing a strong immune response.
Innovation Solution
A method for producing non-exhausted immature dendritic cells from a mixture of allogeneic leukocytes obtained from multiple donors, using an aqueous cell culture medium supplemented with GM-CSF and IL-4, allowing for large-scale and cost-effective production of pro-inflammatory dendritic cells that can be used as 'off-the-shelf' vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If custom-made patient-specific dendritic cell vaccines are produced using traditional methods, then the vaccines can present tumor antigens in an MHC-restricted manner, but the production process is labor-intensive, time-consuming, and results in exhausted cells with weak immune response
Solution Approach 1:
The invention segments the DC production process by separating monocyte isolation from leukapheresis procedures, using pre-isolated monocyte products from healthy donors instead of performing complete leukapheresis for each patient. This segmentation maintains antigen presentation capacity while dramatically reducing production time and labor requirements.
Solution Approach 2:
The invention applies preliminary action by using monocytes that have been pre-isolated and stored from healthy donors before patient treatment. These pre-prepared monocytes are then differentiated into DCs specifically for each patient, combining the benefits of advance preparation with patient-specific customization, thereby improving productivity without sacrificing reliability.
2Productivity
If monocytes are cultivated with GM-CSF and IL-4 for 4-7 days to differentiate into immature DCs, then the DCs are generated, but the cells become exhausted and lose their pro-inflammatory chemokine production capacity
Solution Approach 1:
The invention applies dynamics by optimizing the differentiation time to exactly 5 days and precisely controlling the concentration ratios of GM-CSF and IL-4 in the culture medium. This dynamic control prevents cell exhaustion while maintaining pro-inflammatory chemokine production capacity, resolving the contradiction between productivity and reliability.
Solution Approach 2:
The invention changes critical parameters including the differentiation time (set to 5 days), GM-CSF concentration (1000 U/mL), and IL-4 concentration (1000 U/mL). These parameter optimizations ensure that DCs are generated efficiently while maintaining their ability to produce pro-inflammatory chemokines, thus resolving the contradiction between productivity and reliability.
3Productivity
If allogeneic monocytes from multiple donors are co-cultured, then large-scale production is enabled, but alloreactive T cells and NK cells may prematurely activate the monocytes
Solution Approach 1:
The invention extracts and removes alloreactive T cells and NK cells from the allogeneic leukocyte mixture before monocyte isolation through density gradient centrifugation and magnetic bead separation. This extraction prevents premature monocyte activation while enabling large-scale production from multiple donors, resolving the contradiction between productivity and reliability.
Solution Approach 2:
The invention uses serum-free culture medium as an intermediary environment that prevents premature activation of monocytes during allogeneic co-culture. The specialized medium formulation creates a controlled environment that allows large-scale production from multiple donors while maintaining cell viability and preventing unwanted activation, thus resolving the contradiction between productivity and reliability.
4Quantity of substance
If leukapheresis is performed to obtain billions of monocytes from patient blood, then sufficient monocytes are obtained, but the procedure is laborious and time-consuming
Solution Approach 1:
The invention applies universality by using monocytes from healthy donors that can serve multiple patients rather than performing individual leukapheresis for each patient. This universal approach provides sufficient monocyte quantity for large-scale DC production while eliminating the time-consuming leukapheresis procedure, resolving the contradiction between quantity and time.
Solution Approach 2:
The invention uses monocytes from healthy donors as a substitute (copy) for patient-derived monocytes. These donor monocytes can be differentiated into patient-specific DCs through antigen loading, providing sufficient cell quantity without requiring time-consuming leukapheresis from each patient, thus resolving the contradiction between quantity and time.
Data Source
AI summary
Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating front at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.